BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 7525652)

  • 1. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.
    Synold TW; Relling MV; Boyett JM; Rivera GK; Sandlund JT; Mahmoud H; Crist WM; Pui CH; Evans WE
    J Clin Invest; 1994 Nov; 94(5):1996-2001. PubMed ID: 7525652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.
    Masson E; Relling MV; Synold TW; Liu Q; Schuetz JD; Sandlund JT; Pui CH; Evans WE
    J Clin Invest; 1996 Jan; 97(1):73-80. PubMed ID: 8550853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation.
    Belkov VM; Krynetski EY; Schuetz JD; Yanishevski Y; Masson E; Mathew S; Raimondi S; Pui CH; Relling MV; Evans WE
    Blood; 1999 Mar; 93(5):1643-50. PubMed ID: 10029593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia.
    Panetta JC; Yanishevski Y; Pui CH; Sandlund JT; Rubnitz J; Rivera GK; Ribeiro R; Evans WE; Relling MV
    Cancer Chemother Pharmacol; 2002 Nov; 50(5):419-28. PubMed ID: 12439601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
    Dervieux T; Brenner TL; Hon YY; Zhou Y; Hancock ML; Sandlund JT; Rivera GK; Ribeiro RC; Boyett JM; Pui CH; Relling MV; Evans WE
    Blood; 2002 Aug; 100(4):1240-7. PubMed ID: 12149204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease.
    Göker E; Lin JT; Trippett T; Elisseyeff Y; Tong WP; Niedzwiecki D; Tan C; Steinherz P; Schweitzer BI; Bertino JR
    Leukemia; 1993 Jul; 7(7):1000-4. PubMed ID: 7686600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia.
    Barredo JC; Synold TW; Laver J; Relling MV; Pui CH; Priest DG; Evans WE
    Blood; 1994 Jul; 84(2):564-9. PubMed ID: 7517720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (greater than 50 chromosomes) B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group study.
    Whitehead VM; Vuchich MJ; Lauer SJ; Mahoney D; Carroll AJ; Shuster JJ; Esseltine DW; Payment C; Look AT; Akabutu J
    Blood; 1992 Sep; 80(5):1316-23. PubMed ID: 1381244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.
    Jaramillo AC; Cloos J; Lemos C; Stam RW; Kaspers GJL; Jansen G; Peters GJ
    Leuk Res; 2019 Apr; 79():45-51. PubMed ID: 30849662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.
    Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L
    J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine.
    Dervieux T; Hancock M; Evans W; Pui CH; Relling MV
    Leukemia; 2002 Feb; 16(2):209-12. PubMed ID: 11840287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells.
    Panetta JC; Sparreboom A; Pui CH; Relling MV; Evans WE
    PLoS Comput Biol; 2010 Dec; 6(12):e1001019. PubMed ID: 21152005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia.
    Kinoshita A; Kurosawa Y; Kondoh K; Suzuki T; Manabe A; Inukai T; Sugita K; Nakazawa S
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):256-60. PubMed ID: 12655445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells.
    Cheng Q; Wu B; Kager L; Panetta JC; Zheng J; Pui CH; Relling MV; Evans WE
    Pharmacogenetics; 2004 Aug; 14(8):557-67. PubMed ID: 15284538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia.
    Lin JT; Tong WP; Trippett TM; Niedzwiecki D; Tao Y; Tan C; Steinherz P; Schweitzer BI; Bertino JR
    Leuk Res; 1991; 15(12):1191-6. PubMed ID: 1722550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy.
    Nersting J; Nielsen SN; Grell K; Paerregaard M; Abrahamsson J; Lund B; Jonsson OG; Pruunsild K; Vaitkeviciene G; Kanerva J; Schmiegelow K;
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):53-60. PubMed ID: 30324220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
    Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
    Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of methotrexate polyglutamates in lymphoblast preparations from bone marrow and blood, and the contribution of residual red blood cells.
    Weigand M; Frei E; Graf N; Wiessler M
    J Cancer Res Clin Oncol; 2000 Jul; 126(7):407-11. PubMed ID: 10929763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time course of methotrexate polyglutamate formation and degradation in the pre-B-leukaemia cell line Nalm6 and in lymphoblasts from children with leukaemia.
    Buchholz B; Frei E; Eisenbarth J; Weigand M; Ludwig R
    Eur J Cancer; 1996 Nov; 32A(12):2101-7. PubMed ID: 9014752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single assessment of methotrexate levels at 42 hours permits safe administration and early discharge in children with lymphoblastic lymphoma and leukemia receiving high-dose methotrexate.
    Totadri S; Srinivasan HN; Joseph LL; Boddu D; Mathew LG; John R
    Pediatr Hematol Oncol; 2021 Aug; 38(5):434-443. PubMed ID: 33764242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.